RxDoctor Payments DataLook up a doctor →

George Christy, MD

Interventional Cardiology · Lake Barrington, ILNPI 1881649697

Payments from drug & device makers

$113,460in general payments, 2019–2025

Across 784 payments — averaging $144.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$101K
  • Boehringer Ingelheim$1K
  • Novartis$1K
  • Amgen$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • AstraZeneca$994
  • plus $6K from 37 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$91,58581%
  • Travel & lodging$4,9124%
  • Food & beverage$16,26314%
  • Education$4010%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$113,460 in reported general payments places this provider in the 85th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$570,842
Medicare patients
1,216
Services billed
4,027

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban265$393,426
EliquisApixaban281$346,917
EntrestoSacubitril/Valsartan75$113,368
JardianceEmpagliflozin60$67,204
Repatha SureclickEvolocumab53$44,191
Dabigatran EtexilateDabigatran Etexilate Mesylate32$12,234
Repatha SyringeEvolocumab22$12,005
Metoprolol Succinate765$11,844
Atorvastatin Calcium661$6,998
Ezetimibe216$5,602
Diltiazem 24hr Er (Cd)Diltiazem Hcl221$4,979
Ranolazine ErRanolazine34$3,668
Rosuvastatin Calcium285$3,251
Carvedilol285$3,146
Metoprolol Tartrate305$3,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$101,228$393,426265 claims
PfizerEliquis$584$346,917281 claims
NovartisEntresto$1,396$113,36875 claims
Boehringer IngelheimJardiance$1,451$67,20460 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Lake Barrington

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →